Novo Nordisk A/S, a biopharmaceutical company, has reported that net income for the fourth quarter ended December 31, 2012 was DKK5.75 billion, or DKK10.53 per diluted share, compared to DKK4.69 billion, or DKK8.33 per diluted share, for the same quarter ended December 31, 2011. For 2013, the company expects sales growth of 8 to 11%.
Sales for the fourth quarter of 2012 were DKK20.96 billion, compared to DKK18.12 billion for the same quarter of 2011.
Net income for the year ended December 31, 2012 was DKK21.43 billion, or DKK38.85 per diluted share, compared to DKK17.09 billion, or DKK29.99 per diluted share, for the year ended December 31, 2011.
Sales for the year ended December 31, 2012 were DKK78.03 billion, compared to DKK66.35 billion for the year ended December 31, 2011.
Lars Rebien Sorensen, president and CEO: "2012 has been another year with strong results for Novo Nordisk driven by the sales growth of Victoza and the two modern insulins NovoRapid and Levemir. We are pleased that Tresiba and Ryzodeg have been approved in key markets like Japan and the EU and look forward to launching Tresiba in several markets in 2013."